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Optimization of post-remission therapies to maintain complete remission and prevent
relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Monitoring patients for measurable residual disease (MRD) is helpful to identify those
at risk for relapse. Hypomethylating agents are being investigated as post-remission
therapy. Identification of recurrent genetic alterations that drive disease progression
has enabled the design of new, personalized approaches to therapy for patients with
AML. Emerging data suggest that targeted post-remission therapy, alone or in combi-
nation with chemotherapy, may improve outcomes. Results of ongoing clinical trials
will further define potential clinical benefits.
1 | INTRODUCTION
In adults with newly diagnosed acute myeloid leukemia (AML), com-
plete remission (CR) generally can be achieved in up to 70% of youn-
ger patients (aged <60 years), and in up to 50% of older patients (aged
≥60 years) with conventional high-intensity induction regimens.1
Despite these relatively high rates of initial response, relapse rates
range from approximately 30% to 35% in younger patients with favor-
able risk factors, to 70% to 80% in older patients with adverse risk
factors.2 The 5-year overall survival (OS) rate ranges from 40% to
50% in patients aged <60 years and from 20% to 30% in patients aged
>60 to 70 years who receive high-intensity chemotherapy regimens.3
Furthermore, in a study of 2551 patients with AML who did not
undergo stem cell transplant, the 10-year progression-free survival
(PFS) rate was 2.4% among patients aged ≥60 years.4
Post-remission therapy (consolidation and maintenance therapy)
for AML aims to maintain and/or prolong remission by eliminating
residual leukemic cells and preventing relapse.1 Categorizing patients
by risk status based on validated cytogenetic and molecular abnormal-
ities (such as mutation status of the nucleophosmin gene [NPM1], the
CCAAT/enhancer binding protein α gene [CEBPA], and the FMS-like
tyrosine kinase receptor 3 [FLT3] gene internal tandem duplication
[ITD]) guides treatment decisions with regard to post-remission ther-
apy.1,5 The National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines for AML1 state that karyotype is the most impor-
tant prognostic factor for rates of remission, risk of relapse, and
OS. The incorporation of molecular abnormalities further refines risk
stratification, and identifies potential targeted therapeutic approaches
at all stages of treatment. A personalized post-remission treatment
strategy that is tailored based on overall risk and specific genetic alter-
ations will be key to improving clinical outcomes.1,5
The current approach to post-remission therapy is for patients with
relatively low risk of relapse to undergo successive cycles of chemother-
apy alone, and for higher risk patients to undergo hematopoietic cell
transplantation (HCT). Allogeneic HCT is typically recommended for
patients with high-risk features (including intermediate- and adverse-risk
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genomic abnormalities), after salvage therapy, and for patients with
secondary AML. Although the use of reduced-intensity conditioning
regimens has enabled more patients with high-risk AML to undergo
allogeneic HCT,6 it may also contribute to higher rates of post-
transplant relapse.7 Unfortunately, relapses occur in both high-risk and
low-risk patients, and outcomes are generally very poor for patients who
experience relapse.8 Therefore, better post-remission therapies are
needed to prevent relapses and improve long-term survival. As such,
optimization of therapy post remission represents a major challenge in
the treatment of patients with AML, and the role of maintenance therapy
has remained somewhat controversial and inadequately tested.
The objectives of this article are to discuss factors that affect
relapse in patients with AML, review non-allogeneic HCT post-
remission strategies, and describe potential new approaches under
investigation.
2 | POST-REMISSION TREATMENT
APPROACHES
2.1 | Consolidation therapy
The NCCN Guidelines for AML provide recommendations for post-
remission therapy based on age (<60 or ≥60 years; Table 1) and risk of
relapse by cytogenetics and molecular abnormalities.1 Post-remission
therapy recommendations from the European LeukemiaNet (ELN) differ
somewhat from those of the NCCN. ELN-recommended consolidation
therapy is determined by both age (younger patients [18-60/65 years]
and older patients [>60/65 years]) and genetic risk (cytogenetic and
molecular; Table 1).5 Over the past 12 months, two targeted therapies
were approved for use in induction and consolidation therapy for
patients with AML: the FLT3 tyrosine kinase inhibitor, midostaurin
(see section 2.2), and the antibody-drug conjugate targeting CD33,
gemtuzumab ozogamicin. In addition, a liposomal formulation of dauno-
rubicin and cytarabine was approved for induction and consolidation
therapy for untreated AML patients with high-risk features.
Gemtuzumab ozogamicin is approved in combination with daunoru-
bicin and cytarabine for the treatment of adults with newly diagnosed
AML whose tumors express the CD33 antigen.9 In the randomized,
open-label, phase 3 ALFA-0701 trial (the basis for approval), previously
untreated patients aged 50 to 70 years who achieved CR to standard
induction therapy, with or without gemtuzumab ozogamicin, received
two consolidation courses of daunorubicin, with or without gemtuzumab
ozogamicin. Patients with CR who received gemtuzumab ozogamicin
had a significantly higher rate of relapse-free survival (RFS) at two years
than controls (50.3% vs 22.7%, respectively; P = .0003).10 In contrast, in
the ECOG E1900 randomized phase 3 trial, 307 patients aged 17 to
60 years with AML who achieved CR after induction therapy (daunorubi-
cin + cytarabine) were randomized to intensive consolidation therapy
with or without gemtuzumab ozogamicin (single 6 mg/m2 dose) before
autologous HCT. The single dose of gemtuzumab ozogamicin did not
demonstrate a disease-free survival (DFS) or OS benefit over control.11
CPX-351, a liposomal formulation of daunorubicin and cytarabine,
is approved for adults with newly diagnosed therapy-related AML
or AML with myelodysplasia-related changes.12 In a randomized,
open-label, phase 3 trial, patients aged 60 to 75 years with newly diag-
nosed secondary AML were randomized to receive up to two cycles of
induction with CPX-351. This was followed by up to two cycles of
CPX-351 consolidation (n = 153), or up to two cycles of conventional
cytarabine/daunorubicin 7 + 3 induction, and up to two cycles of
7 + 3 consolidation (n = 156). At a median follow-up of 20.7 months,
median OS was significantly longer in the CPX-351 group vs the 7 + 3
group (9.56 vs 5.95 months, respectively; P = .003).13
2.2 | Maintenance therapy
The role and benefit of maintenance therapy in adult AML were evalu-
ated more than 30 years ago. This was a trial in which patients
were randomized to receive either no further therapy, or long-term
maintenance chemotherapy following a morphologic CR. Patients who
received no further therapy experienced a significantly shorter duration
of remission compared with patients who received maintenance
chemotherapy. They ultimately relapsed in a median of 4.1 months,
whereas patients who received maintenance chemotherapy relapsed in
a median of 8.1 months (P ≤ .002, log rank).14 The role of maintenance
therapy was tested in a parallel trial, in which previously untreated
patients with AML in CR after induction therapy were randomized to
receive consolidation therapy, with or without monthly chemotherapy-
based maintenance therapy. This was given until relapse or a maximum
of 3 years. Patients who received both consolidation and maintenance
therapy had significantly better outcomes (median duration of remis-
sion of 13 months and 30% continuous remissions at 2.5 years) com-
pared with patients who received consolidation therapy and no
maintenance therapy (median duration of remission of 8 months and
17% continuous remissions at 2.5 years); P = .003; Figure 1).15
Since these initial observations, a number of regimens have been
evaluated as maintenance therapies in patients with AML. In the ran-
domized, double-blind, placebo-controlled phase 3 RATIFY trial, oral
midostaurin was added to consolidation therapy with cytarabine
and was given as single-agent maintenance therapy. After a median
follow-up of 59 months, results showed that midostaurin significantly
prolonged OS vs placebo (median, 74.7 months vs 25.6 months, respec-
tively; P = .009), and decreased the risk of death by 22% (P = .009). The
4-year OS rate was 51.4% in the midostaurin group vs 44.3% in the
placebo group. Based on these findings, midostaurin is approved by
the US Food and Drug Administration (FDA) for the treatment of
adults with FLT3 mutation-positive AML in combination with standard
cytarabine consolidation. Although a subset of patients in the trial
underwent HCT, and trial therapy was discontinued at the time of trans-
plantation, the risk of death was 24.3% lower with midostaurin vs pla-
cebo after censoring data from patients who underwent transplantation.
The 4-year OS rate was 63.7% in the midostaurin group vs 55.7% in the
placebo group in this subset, which was not statistically significant.16
The FDA did not approve midostaurin as maintenance therapy because
the design of the trial did not allow for determination of the indepen-
dent effect of maintenance therapy. However, in Europe, midostaurin is
approved for the treatment of newly diagnosed patients with FLT3-
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mutated AML in combination with standard daunorubicin/cytarabine
induction followed by high-dose cytarabine (HiDAC) consolidation,
and as single-agent maintenance therapy for patients in complete
response.17,18 In an unplanned subset analysis of 174 patients in CR at
the start of maintenance therapy, no difference was observed in DFS
and OS between the midostaurin and placebo arms during 12 cycles of
maintenance therapy.19
A prospective phase 3 study compared low-dose cytarabine
(LDAC) maintenance therapy vs observation in 86 patients with AML,
aged 18 to 70 years, who achieved CR to induction therapy with
TABLE 1 Summary of National Comprehensive Cancer Network1 and European LeukemiaNet Guidelines for post-remission therapy in
patients with AML5
National Comprehensive Cancer Network
Patients aged <60 y with
favorable risk
• HiDAC 3 g/m2 over 3 h every 12 h on days 1, 3, 5 or 1, 2, 3 × 3-4 cycles, or
• Cytarabine 1000 mg/m2 every 12 h on days 1-4 + daunorubicin 60 mg/m2 on day 1 (first cycle) or days 1-2
(second cycle) + gemtuzumab ozogamicin 3 mg/m2 on day 1 × 2 cycles (CD33-positive)
Patients aged <60 y with
intermediate risk
• Matched sibling or alternative donor HCT, or
• HiDAC 1.5-3 g/m2 over 3 h every 12 h on days 1, 3, 5 or 1, 2, 3 × 3-4 cycles, or
• HiDAC 1.5-3 g/m2 over 3 h every 12 h on days 1, 3, 5 or 1, 2, 3 with oral midostaurin 50 mg every 12 h on
days 8-21 (FLT3-mutated AML), or
• Cytarabine 1000 mg/m2 every 12 h on days 1-4 + daunorubicin 60 mg/m2 on day 1 (first cycle) or days 1-2
(second cycle) + gemtuzumab ozogamicin 3 mg/m2 on day 1 × 2 cycles (CD33-positive)
Patients aged <60 y with
treatment-related disease other
than CBF and/or with poor risk
• Matched sibling or alternative donor HCT, or
• HiDAC 1.5-3 g/m2 every 12 h on days 1, 3, 5 or 1, 2, 3 × 3-4 cycles, or
• HiDAC 1.5-3 g/m2 every 12 h on days 1, 3, 5 or 1, 2, 3 with oral midostaurin 50 mg every 12 h on days 8-21
(FLT3-mutated AML), or
• Dual-drug liposomal encapsulation cytarabine 65 mg/m2 and daunorubicin 29 mg/m2 on days 1 and 3
(cytotoxic therapy-related AML or patients with antecedent MDS/CMML or cytogenetic changes consistent
with MDS)
Patients aged ≥60 y with CR after
intensive induction therapy
• Reduced-intensity HCT, or
• Standard-dose cytarabine with or without an anthracycline (idarubicin or daunorubicin) or intermediate-dose
cytarabine for 4-6 doses for 1 or 2 cycles (if good performance status, normal renal function, better-risk or
normal karyotype and favorable molecular markers), or
• Dual-drug liposomal encapsulation cytarabine 65 mg/m2 and daunorubicin 29 mg/m2 on days 1 and 3
(cytotoxic therapy-related AML or patients with antecedent MDS/CMML or cytogenetic changes consistent
with MDS), or
• Cytarabine 1000 mg/m2 every 12 h on days 1-4 + daunorubicin
60 mg/m2 on day 1 (first cycle) or days 1-2 (second cycle) + gemtuzumab ozogamicin 3 mg/m2 on day
1 × 2 cycles (CD33-positive), or
• Maintenance therapy with hypomethylating agents (5-azacitidine, decitabine) every 4-6 weeks until
progression (if patient received hypomethylating agents during induction)
Patients aged ≥60 y with CR after
lower intensity therapy
• Reduced-intensity HCT
• Hypomethylating agents (5-azacitidine or decitabine) every 4-6 weeks until progression
• Gemtuzumab ozogamicin 2 mg/m2 on day 1 every 4 weeks up to 8 continuation courses (CD33-positive)
• Continue enasidenib (IDH2-mutated AML) or ivosidenib (IDH1-mutated AML) until progression
European LeukemiaNet
Younger patients (18–60/65 y)
Favorable risk genetics • 2 to 4 cycles of IDAC (1000-1500 mg/m2 every 12 h, days 1-3 or days 1-5 or 6) additional therapy
• Midostaurin for patients with FLT3 mutations (administered after the chemotherapy)
Intermediate risk genetics • Allogeneic HCT from matched-related or unrelated donor, or
• 2 to 4 cycles of IDAC, or
• High-dose therapy and autologous HCT
• Midostaurin for patients with FLT3 mutations (administered after the chemotherapy)
Adverse risk genetics • Allogeneic HCT from matched-related or unrelated donor
• Midostaurin for patients with FLT3 mutations (administered after the chemotherapy)
Older patients (>60/65 y)
Favorable risk genetics • 2 to 3 cycles of IDAC (500-1000 mg/m2 every 12 h, days 1-3 or days 1-5 or 6)
Intermediate/adverse risk
genetics
• No established value; consider allogeneic HCT with a low HCT-Comorbidity Index, or investigational
therapy
Abbreviations: AML, acute myeloid leukemia; CBF, core-binding factor; CMML, chronic myelomonocytic leukemia; CR, complete remission;
HiDAC, high-dose cytarabine; HCT, hematopoietic cell transplant; IDAC, intermediate dose cytarabine; MDS, myelodysplastic syndrome.
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HiDAC and amsacrine (when given after relapse or refractoriness to
prior induction therapy). LDAC maintenance therapy (10 mg/m2 every
12 hours x 21 days every 8 weeks) was initiated within 1 to 3 weeks
of CR. Although the regimen was tolerable, and leukemia-free survival
was significantly prolonged with LDAC vs observation (7.7 months vs
3.1 months, respectively; P = .027), OS was not significantly pro-
longed (10.8 months vs 7.0 months, respectively; P = NS).20
The role of hypomethylating agents as maintenance therapy in
AML remains under investigation. In a recent randomized phase
3 study (HOVON 97), post-consolidation maintenance therapy with
azacitidine (50 mg/m2 × 5 days every 4 weeks for up to 12 cycles)
was compared with observation (control) in patients aged ≥60 years.
The patients had AML, or myelodysplastic syndrome (MDS) with
excess of blasts and were in CR after ≥2 cycles of intensive chemother-
apy. In 115 patients analyzed, maintenance therapy with azacitidine
improved 12-month DFS over control (64% vs 42%, respectively;
P = .04). After censoring data from patients who received allogeneic
HCT, the investigators determined that the 12-month OS rate was 82%
in the azacitidine group and 63% in the control group (P = .209).21 A
phase 2 study with azacitidine (60 mg/m2 × 5 days every 28 days as
maintenance therapy initiated within 28 days of CR to standard induc-
tion chemotherapy) was conducted. The study had 23 patients aged
≥60 years with high-risk MDS, or AML following MDS, and showed no
DFS or OS benefit.22 Also, assessment of survival with decitabine
(20 mg/m2 × 5 days every 6 weeks for 8 cycles) in patients aged
<60 years with AML in CR after consolidation therapy showed no ben-
efit in terms of DFS and OS when compared with historical controls.23
Thus, the use of maintenance therapy remains controversial.
A 2016 systematic literature review of 50 studies assessed the avail-
able evidence for the use of maintenance therapy after consolidation
therapy or HCT.24 At the time of publication, the authors did not
recommend maintenance therapy after adequate induction and con-
solidation therapy or after allogeneic HCT, with the exceptions of clin-
ical trial investigation and the use of midostaurin for induction,
consolidation, and maintenance therapy in FLT3-mutated AML
(although, as mentioned previously, the FDA did not approve
midostaurin for maintenance therapy). One reason was the inability to
make definitive conclusions regarding the benefits of maintenance
therapy, based on data from older trials using induction and consolida-
tion regimens that are no longer standard; (Other reasons included)
missing details from those trials and alternative designs used in those
trials. Also noted was the lack of randomized studies demonstrating
the efficacy of maintenance therapy after allogeneic HCT.24 Never-
theless, maintenance therapy in patients with AML after remission
remains an active area of investigation (discussed below).
2.3 | Post-HCT relapse prevention
HCT is recommended after induction failure, residual disease, or as
post-remission therapy in properly selected patients.1 HCT after first
CR can improve the prognosis of patients with AML; however, the
possibility of relapse—the leading cause of treatment failure—is signifi-
cant.25,26 Furthermore, relapse after HCT is associated with poor out-
comes.27 Thus, strategies to avoid relapse following HCT are needed.
Hypomethylating agents, the most commonly used non-targeted
therapies in patients who relapse after HCT, may be effective in
preventing post-HCT relapse by inducing a graft-vs-leukemia response
through increased expression of tumor antigens.25 In a phase 1/2 trial
in 27 patients with AML who had undergone a reduced-intensity condi-
tioning regimen with HCT, azacitidine (36 mg/m2 subcutaneously for
5 days in up to 10, 28-day cycles) after HCT (beginning day 42) induced
an increase in circulating regulatory T cells and was well tolerated, with-
out inducing significant graft-vs-host disease.28 A randomized phase 3
study compared azacitidine (32 mg/m2 subcutaneously for 5 days in up
to 12, 28-day cycles; n = 87) vs no further intervention in patients with
AML, chronic myelomonocytic leukemia, or MDS after remission with
HCT (NCT00887068)29; the study was terminated early due to slow
accrual. At a median follow-up of 4.6 years in the azacitidine group and
4.1 years in the control group, no significant effects on relapse-free sur-
vival were observed with azacitidine therapy. However, a nonsignificant
trend toward improvement in relapse-free survival with azacitidine was
observed in the subgroup of patients who received at least 9 cycles of
treatment. Decitabine (5-15 mg/m2 intravenously for 5 days for up to
8, 6-week cycles) demonstrated favorable results as post-HCT mainte-
nance (50-100 days post-HCT) in patients with AML (n = 17) or MDS
(n = 5). Eight of nine patients who completed study treatment remained
in remission through the end of the investigation.30 An investigational
oral hypomethylating agent, CC-486, which provides extended dosing
to prolong activity, was evaluated in a phase 1/2 study of patients with
AML (n = 26) or MDS (n = 4) who had undergone HCT. In 28 evaluable
patients, CC-486 (200-300 mg orally for 7 days or 150-200 mg orally
for 14 days in up to 12, 28-day cycles administered post-HCT) resulted
in 1-year relapse or PFS rates of 54% with a 7-day regimen, and 72%





















F IGURE 1 Life-table analysis of duration of remission following
induction, then consolidation, with (dark line; n = 71) and without
(hatched line; n = 74) long-term monthly maintenance in patients with
AML. Reprinted with permission from Buchner T, Urbanitz D,
Hiddemann W, et al. Intensified induction and consolidation with or
without maintenance chemotherapy for acute myeloid leukemia
(AML): two multicenter studies of the German AML Cooperative
Group. J Clin Oncol. 1985;3(12):1583-158915
806 MEDEIROS ET AL.
with a 14-day regimen. Estimated 1-year survival rates were 86% and
81%, respectively.31
For patients with FLT3-ITD AML, many FLT3 tyrosine kinase
inhibitors are under investigation for post-HCT maintenance, includ-
ing sorafenib, midostaurin, quizartinib, crenolanib, and gilteritinib. In
an early-phase study of 22 patients with FLT3-ITD AML treated with
sorafenib following HCT, PFS and OS rates at 1 year were 85%
and 95%, respectively.32 In a retrospective analysis, patients with
FLT3-ITD AML treated with sorafenib maintenance after HCT during
the first CR (n = 26) were compared with matched patients who were
not treated with sorafenib (n = 55). The treated patients showed sig-
nificantly improved 2-year OS (81% vs 62%, P = .029), PFS (82% vs
53%, P = .0081), and a lower relapse rate (8.2% vs 37.7%, P = .0077)
compared with patients not treated with sorafenib.33
Midostaurin maintenance was investigated in a phase 2 trial that
included 40 patients with newly diagnosed FLT3-ITD AML post HCT.
The trial showed a low incidence of relapse in patients with both high
and low FLT3-ITD mutant to wild type ratio (5% and 12%, respec-
tively).34 A randomized, open-label, phase 2 exploratory trial (RADIUS)
compared midostaurin in combination with standard of care vs standard
of care in newly diagnosed patients (n = 60) with FLT3-ITD AML who
were in first CR after HCT.35 The addition of midostaurin resulted in a
46% relative reduction in the risk of relapse at 18 months. There were
estimated relapse rates of 11% and 24% in the midostaurin/standard of
care and standard of care groups, respectively; median relapse-free sur-
vival was not reached at 18 months, and follow-up is ongoing.
A randomized, double blind, placebo-controlled study (SORMAIN)
compared sorafenib maintenance vs placebo in patients (n = 83), with
FLT3-ITD AML in complete hematologic remission after HCT.36 At a
median follow up of 41.8 months after randomization, median relapse-
free survival was 30.9 months in the placebo group vs not reached in
the sorafenib group. This corresponded to a 2-year relapse-free survival
rate of 53% with placebo vs 85% with sorafenib (P = .0135).
Quizartinib was evaluated as maintenance therapy in patients
(n = 13) with CR post HCT in a phase 1 study; nine patients survived
for at least 50 weeks and 4 patients survived for more than 2 years.37
An ongoing phase 3 study (QUANTUM-R; NCT02039726) includes an
evaluation of quizartinib as post-transplant maintenance, and cre-
nolanib also is under investigation in this setting (NCT02400255).
A large, prospective, placebo-controlled, randomized phase 3 study
of nearly 350 patients is underway to determine the benefit of
gilteritinib as post-HCT maintenance therapy in FLT3-ITD AML during
the first CR (NCT02997202). Results of ongoing research will further
define the potential benefits of post-HCT maintenance therapy in
patients with AML.
2.4 | Minimal residual disease and post-remission
therapy
Identification of patients at high risk for disease relapse allows for the
use of tailored post-remission treatment approaches to avoid or delay
relapse. Evaluations of minimal residual disease (MRD) after CR with
induction therapy are informative because MRD is an important
determinant of relapse risk and survival. Methods used to measure
MRD include flow cytometry, real-time quantitative polymerase chain
reaction (RT-qPCR), and targeted next-generation sequencing (NGS).
Use of multiparameter flow cytometry to detect MRD in 186 adults
(median age, 51 years; range, 17-77 years) with AML showed that
achievement of MRD− status at CR, during consolidation (median
of two cycles, 3-7 months after initiation), and at completion of
intermediate-dose cytarabine (IDAC) and idarubicin-based therapy
(≥8 months) was highly prognostic for OS. The hazard ratio (95%
confidence interval [CI]) for OS was 5.17 (1.98-13.49) for MRD at
CR (P = .0008), 12.57 (3.94-40.07) for MRD during consolidation
(P < .0001) 10.19 (2.34-44.34) for MRD at completion of therapy
(P = .002).38
In a recent study, prospective flow cytometric measurement of
MRD after each cycle of standard induction therapy was used to inves-
tigate outcomes in a heterogeneous cohort of 2450 patients aged
<60 years. After one cycle of induction therapy, patients were divided
into risk groups based on a validated system that incorporated cytoge-
netics, mutation status, and clinical factors. Standard-risk patients
received a second cycle of induction therapy, with a subset subse-
quently receiving HiDAC consolidation and HCT. The MRD responses
in all patients after cycle one predicted OS. The OS in patients with
residual disease, partial remission, MRD+, and MRD− were 25%, 36%,
43%, and 63%, respectively (P < .0001). Results suggest that this
method may help identify patients with standard risk who may benefit
from HCT after first remission.39 Monitoring of MRD by RT-qPCR in
346 patients with NPM1-mutated AML (median age, 50 years; range,
6-68 years) showed MRD in the peripheral blood after two cycles of
intensive chemotherapy was highly prognostic for death, with a hazard
ratio (95% CI) of 4.84 (2.57-9.15; P < .001). The 5-year OS rate was
73% in MRD− patients and 24% in MRD+ patients (P < .001). Further-
more, no significant benefit of HCT was observed in MRD+ patients in
this study, although the number of patients analyzed was small.40 In a
recent study, targeted NGS carried out during CR to induction therapy
in patients with AML frequently detected persistent mutations in DTA
genes (DNMT3A, TET2, ASXL1), which are associated with age-related
clonal hematopoiesis. These mutations did not correlate with an
increased risk of relapse based on 4-year relapse rates; however,
coexisting persistent non-DTA mutations in patients with persistent
DTA mutations were highly prognostic for relapse (P = .002). In addi-
tion, the persistence of non-DTA mutations among all patients was
associated with an increased risk of relapse (P = .001), reduced RFS
(P = .006), and reduced OS (P = .01).41 Recently, NGS-MRD monitoring
in AML was shown to be predictive for post-transplant relapse and sur-
vival when used in patients with CR prior to allogeneic HCT,42 and to
be prognostic for relapse and mortality when used in patients on day
21 after allogenic HCT.43
Although MRD negativity is highly prognostic for outcomes in
AML,44 until recently, a drawback to the use of MRD monitoring was
that there was no consensus on determining MRD. Lack of standardi-
zation and lack of established cutoff values had limited the wide-
spread use of MRD to guide treatment.1 In March 2018, however,
flow cytometric, molecular, and clinical MRD recommendations made
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by consensus of an international panel of experts were published.44
Moving forward, these recommendations should provide uniform
guidance for the use of MRD to optimize outcomes in AML.
While the prognostic value of MRD is clear, current definitions of
CR do not account for MRD, and there are no clear guidelines on how
to manage high-risk patients once they are identified. The impact of
MRD on survival was assessed in 359 patients (median age at HCT,
50 years; range, 18-75 years) in MRD+ CR, MRD− CR, or with active
AML before allogeneic HCT. After transplant, the estimated 3-year
OS rate of the 76 MRD+ patients (26%) was similar to that of the
48 patients with active AML (23%), whereas the estimated 3-year OS
rate of the 235 MRD- patients was 73%. Multivariable hazard ratio
(95% CI) for death was 3.69 (2.51-5.42) for patients with MRD+
status (P < .001) and 4.40 (2.56-7.55) for patients with active AML
(P < .001).45 These results highlight the prognostic importance of
MRD and suggest that morphology-based assessments of CR alone
are not ideal.45 In an ongoing phase 2 study (RELAZA2), preemptive
treatment with 6 cycles of azacitidine (75 mg/m2 × 7 days) and MRD
risk-adapted treatment for up to 18 additional months was evaluated.
This was done in patients aged ≥18 years with MRD while in CR after
conventional chemotherapy only, or consecutive allogeneic HCT. Pre-
emptive MRD risk-adapted treatment prevented or substantially del-
ayed disease relapse in 31 of 53 patients who were still in CR after
6 months (58%; 95% CI: 44-72; P < .001).46 These results are encour-
aging; however, future evaluation is needed to identify effective strat-
egies for MRD+ patients.
2.5 | Future directions: post-remission therapies
under investigation
Selected studies evaluating maintenance therapies in patients with
AML are summarized in Table S1. Hypomethylating agents under inves-
tigation as maintenance therapies in AML include guadecitabine (SGI-
110) and CC-486, an oral formulation of azacitidine. Guadecitabine
achieved a composite complete response that ranged from 50% to 59%
(depending on schedule used) in treatment-naive patients with AML
aged ≥65 years in a randomized, open-label, phase 1/2 study.47
A phase 2 clinical trial involving maintenance therapy (up to 24 months)
with guadecitabine with or without idarubicin in previously untreated
elderly patients (aged ≥70 years) with AML is ongoing (NCT02096055).
CC-486 is being evaluated as maintenance therapy in a randomized,
double-blind, placebo-controlled phase 3 trial in patients aged
≥55 years with newly diagnosed AML or AML secondary to prior MDS
(NCT01757535). It is hoped that results from this trial will expand
treatment options for older patients with AML.48
Enasidenib (AG-221), which is an isocitrate dehydrogenase (IDH)
2 inhibitor approved for use in relapsed or refractory AML with IDH2
mutation,49 is currently being investigated in patients with newly diag-
nosed AML in a phase 1 trial (NCT02632708). This is in combination
with induction therapy (cytarabine + daunorubicin or idarubicin) and
consolidation therapy (mitoxantrone + etoposide or cytarabine), and
enasidenib may be continued as daily maintenance therapy for a total
treatment period of up to 2 years. The trial is also evaluating the IDH1
inhibitor ivosidenib (AG-120) in a similar treatment plan. Ivosidenib, an
oral inhibitor of mutant IDH1, is approved by the FDA for the treatment
of patients with relapsed/refractory AML with IDH1 mutation.50
A phase 1, multicenter, dose-escalation study demonstrated an overall
response rate of 39.1% and CR rate of 21.8% with ivosidenib 500 mg
orally daily in patients with relapsed/refractory AML and IDH1 muta-
tion (n = 179).51 In addition, the NCCN guidelines recommend continu-
ation of ivosidenib therapy post remission until disease progression in
patients >60 years of age with IDH1 mutation who respond to prior
lower-intensity therapy.1
FLT3 inhibitors under investigation include quizartinib, crenolanib,
and gilteritinib. Quizartinib has shown activity in patients with
relapsed/refractory AML and is being investigated in the ongoing
QuANTUM-First randomized, double-blind, phase 3 study. Evaluation
as post-remission therapy involves the addition of quizartinib or placebo
to consolidation therapy (up to 4 cycles of cytarabine) and continued
quizartinib or placebo as maintenance therapy for up to 12 cycles in
patients with FLT3-mutated AML (NCT02668653). Crenolanib is being
studied in combination with consolidation therapy (up to 4 cycles of
HiDAC), and continued as maintenance therapy for up to 12 months, in
an ongoing trial of patients aged ≤60 years with FLT3-mutated AML.52
Gilteritinib (ASP2215) has shown activity in relapsed/refractory FLT3-
mutated AML. It is currently being studied in an open-label, phase 1 trial;
evaluation as post-remission therapy involves administration combina-
tion with HiDAC consolidation followed by single-agent maintenance
therapy with gilteritinib once daily, in 28-day cycles, for up to 26 cycles
in patients aged ≥18 years (NCT02236013).53
Results of a phase 2 trial demonstrated that sorafenib, a multi-
targeted kinase inhibitor that also inhibits FLT3, added to IDAC
consolidation therapy and administered twice daily as single-agent
maintenance therapy in 28-day cycles for up to 12 cycles in older
patients (aged ≥60 years) with FLT3-mutated AML, improved 1-year
OS rates (62% for FLT3 ITD compared with 30% for elderly historical
controls).54 In the randomized, phase 2 SORAML trial, sorafenib was
added to consolidation therapy in patients aged <60 years with and
without mutated FLT3. Sorafenib was continued for up to 1 year as
maintenance therapy after completion of planned consolidation ther-
apy. Addition of sorafenib resulted in significantly longer event-free
survival (EFS), and a 36% reduction in the risk of relapse or death after
prolonged follow-up, compared with placebo. The 5-year OS rate
showed a trend for improvement with sorafenib; it was 61% with
sorafenib vs 50% with placebo.55 In contrast, dasatinib did not
improve DFS when used as single-agent maintenance therapy in a
phase 2 study in 26 patients (7 with KIT mutations; 6 with FLT3 muta-
tions; aged 18-60 years) with core binding factor-AML in first CR.56
Maintenance therapy with immune-mediated therapies is being
investigated in clinical trials. The immune checkpoint inhibitor nivolumab
is currently under investigation in ongoing phase 2 clinical trials in
patients aged ≥18 years with high-risk AML, in remission, who were not
considered for allogeneic HCT. Preliminary results with nivolumab in
patients in CR were reported in 14 patients (median age, 56 years) after
a median follow-up of 11 months (range, 1.4-26 months) showed 6-
and 12-month CR rates of 79% and 71%, respectively, and 12- and
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18-month OS rates of 86% and 67%, respectively; the regimen is well
tolerated.57 Nivolumab is also under investigation in an ongoing ran-
domized phase 2 trial (REMAIN) that is comparing surveillance and
single-agent therapy with nivolumab for AML in patients, post consoli-
dation, who are not candidates for HCT (NCT02275533). Results are
expected in June 2019.
The immune stimulator lenalidomide is being evaluated in a phase
2 trial as post-induction and consolidation therapy in patients with
high-risk AML. Preliminary results with lenalidomide after a median of
nine treatment cycles, and a median follow-up of 19 months (range,
8.5-39 months), indicate an early signal for improved 6-month and
12-month RFS (100% and 69%, respectively) as well as 6-month and
12-month OS (100% and 90%, respectively) in 14 patients (median
age, 57.5 years; range, 23-67 years) the regimen is well tolerated.58
Lenalidomide is also being evaluated as a maintenance therapy after
addition to standard induction therapy in a prospective, randomized,
phase 3 study (HOVON 132) in patients aged 18-65 years; accrual
was completed in August 2017 and results are forthcoming.59
Combination immunotherapy with histamine dihydrochloride and
interleukin-2 to enhance cytotoxic antileukemic lymphocyte function
was investigated in an open-label, phase 3 trial in 321 adults (median
age, 57 years; range, 18-84 years). Patients in CR were stratified by
CR1 or CR >1 and randomized to receive combination therapy or no
treatment.60 Combination therapy was tolerable and significantly
improved leukemia-free survival vs no treatment ≥3 years after the
last patient was enrolled. This was true for all patients (34% vs 24%,
respectively; P < .01) and for the subset of patients in CR1 at random-
ization (40% vs 26%, respectively; P < .01).
The effects of addition or no addition of the androgen nore-
thandrolone to maintenance therapy with mercaptopurine and meth-
otrexate, during the post-induction phase, was investigated in a
randomized phase 3 study in 325 elderly patients (median age,
70 years) with AML.61 All patients received induction therapy with
idarubicin, cytarabine, and lomustine. Addition of norethandrolone at
20 mg/day to maintenance therapy for 2 years improved the 5-year
DFS rate (31.2% vs 16.2%; P = .002), EFS rate (21.5% vs 12.9%; P value
not provided), and OS rate (26.3% vs 17.2%; P = .008) compared with
no addition of norethandrolone.
3 | CONCLUSIONS
New strategies are needed to prolong remission and improve survival
in patients with AML after CR with induction therapy. Traditional con-
solidation strategies include the use of single-agent IDAC or HiDAC
or cytarabine-based consolidation regimens, continuing with the same
induction regimen that achieved CR, or using allogeneic HCT.1 Emerg-
ing data suggest that targeted therapy and combinations of chemo-
therapy and targeted agents may improve outcomes. Research
regarding the benefits of maintenance therapy in patients with AML
has been inconclusive to date. However, trials to evaluate new agents
and new combination therapies as maintenance therapy, including for
the prevention of relapse after HCT, are in progress. In addition, given
the known heterogeneity of AML, an important goal moving forward
is to identify predictive biomarkers of response to specific mainte-
nance therapies. The ultimate goal is to identify regimens that will pro-
long survival in patients with AML by achieving and maintaining the
best response for as long as possible.
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